XTX Topco Ltd Lowers Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

XTX Topco Ltd decreased its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 27.9% during the third quarter, Holdings Channel.com reports. The institutional investor owned 43,664 shares of the biotechnology company’s stock after selling 16,922 shares during the quarter. XTX Topco Ltd’s holdings in CytomX Therapeutics were worth $52,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in CTMX. US Bancorp DE bought a new position in shares of CytomX Therapeutics during the third quarter valued at about $40,000. Forefront Analytics LLC grew its stake in shares of CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 43,176 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of CytomX Therapeutics by 96.6% in the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 40,309 shares during the last quarter. Candriam S.C.A. purchased a new position in CytomX Therapeutics during the 2nd quarter valued at about $256,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in CytomX Therapeutics by 10.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after buying an additional 26,373 shares during the period. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Monday, November 11th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.77.

CytomX Therapeutics Trading Down 0.9 %

CTMX opened at $1.09 on Monday. The stock has a fifty day simple moving average of $1.06 and a two-hundred day simple moving average of $1.20. The company has a market cap of $85.30 million, a price-to-earnings ratio of 6.41 and a beta of 1.07. CytomX Therapeutics, Inc. has a 12-month low of $0.83 and a 12-month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $18.92 million. During the same period in the prior year, the firm posted $0.04 earnings per share. On average, analysts predict that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.